Switch theme
Sign up to access all valuation multiples
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.
2011
n/a
LTM Revenue $405M
LTM EBITDA $91.8M
$5.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SK Biopharmaceuticals has a last 12-month revenue of $405M and a last 12-month EBITDA of $91.8M.
In the most recent fiscal year, SK Biopharmaceuticals achieved revenue of $373M and an EBITDA of $68.6M.
SK Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SK Biopharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $242M | $373M | XXX | XXX | XXX |
| Gross Profit | $142M | $219M | XXX | XXX | XXX |
| Gross Margin | 59% | 59% | XXX | XXX | XXX |
| EBITDA | -$13.8M | $68.6M | XXX | XXX | XXX |
| EBITDA Margin | -6% | 18% | XXX | XXX | XXX |
| Net Profit | -$95.0M | -$22.4M | XXX | XXX | XXX |
| Net Margin | -39% | -6% | XXX | XXX | XXX |
| Net Debt | $27.0M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, SK Biopharmaceuticals's stock price is KRW 103000 (or $70).
SK Biopharmaceuticals has current market cap of KRW 8.07T (or $5.5B), and EV of KRW 7.93T (or $5.4B).
See SK Biopharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.4B | $5.5B | XXX | XXX | XXX | XXX | $1.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, SK Biopharmaceuticals has market cap of $5.5B and EV of $5.4B.
SK Biopharmaceuticals's trades at 13.3x LTM EV/Revenue multiple, and 58.8x LTM EBITDA.
Analysts estimate SK Biopharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SK Biopharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.4B | XXX | XXX | XXX |
| EV/Revenue | 14.5x | XXX | XXX | XXX |
| EV/EBITDA | 78.7x | XXX | XXX | XXX |
| P/E | 33.5x | XXX | XXX | XXX |
| P/E/Growth | 6.5x | XXX | XXX | XXX |
| EV/FCF | 97.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSK Biopharmaceuticals's NTM/LTM revenue growth is 29%
SK Biopharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, SK Biopharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SK Biopharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SK Biopharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 54% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -597% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 48% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 75% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SK Biopharmaceuticals acquired XXX companies to date.
Last acquisition by SK Biopharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . SK Biopharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was SK Biopharmaceuticals founded? | SK Biopharmaceuticals was founded in 2011. |
| Where is SK Biopharmaceuticals headquartered? | SK Biopharmaceuticals is headquartered in South Korea. |
| Who is the CEO of SK Biopharmaceuticals? | SK Biopharmaceuticals's CEO is Mr. Dong-Hoon Lee. |
| Is SK Biopharmaceuticals publicy listed? | Yes, SK Biopharmaceuticals is a public company listed on KRX. |
| What is the stock symbol of SK Biopharmaceuticals? | SK Biopharmaceuticals trades under 326030 ticker. |
| When did SK Biopharmaceuticals go public? | SK Biopharmaceuticals went public in 2020. |
| Who are competitors of SK Biopharmaceuticals? | Similar companies to SK Biopharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SK Biopharmaceuticals? | SK Biopharmaceuticals's current market cap is $5.5B |
| What is the current revenue of SK Biopharmaceuticals? | SK Biopharmaceuticals's last 12-month revenue is $405M. |
| What is the current EBITDA of SK Biopharmaceuticals? | SK Biopharmaceuticals's last 12-month EBITDA is $91.8M. |
| What is the current EV/Revenue multiple of SK Biopharmaceuticals? | Current revenue multiple of SK Biopharmaceuticals is 13.3x. |
| What is the current EV/EBITDA multiple of SK Biopharmaceuticals? | Current EBITDA multiple of SK Biopharmaceuticals is 58.8x. |
| What is the current revenue growth of SK Biopharmaceuticals? | SK Biopharmaceuticals revenue growth between 2023 and 2024 was 54%. |
| Is SK Biopharmaceuticals profitable? | Yes, SK Biopharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
